1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2016

Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2016" provides an overview of Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Proliferative Diabetic Retinopathy (NPDR). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by G7 Countries: Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials in E7 Countries by Trial Status 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profile Snapshots 28
Appendix 49
Abbreviations 49
Definitions 49
Research Methodology 50
Secondary Research 50
About GlobalData 51
Contact Us 51
Disclaimer 51
Source 52

List of Tables
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 9
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 13
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 16
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Phase, 2016* 19
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 20
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 24
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27

List of Figures
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 9
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 13
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Non-Proliferative Diabetic Retinopathy (NPDR) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 16
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 19
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 20
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 24
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
Non-Proliferative Diabetic Retinopathy (NPDR) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27
GlobalData Methodology 50

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Europe Market Report for Fundus Cameras 2017 - MedCore

Europe Market Report for Fundus Cameras 2017 - MedCore

  • $ 6495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description General Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapte ...

Europe Market Report for Slit Lamps 2017 - MedCore

Europe Market Report for Slit Lamps 2017 - MedCore

  • $ 5995
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description General Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapte ...

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Glaucoma Therapeutics Market: Overview Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.